TABLE 2.
Baseline characteristics of relapsed ALL patients with or without NR3C1 mutations.
| Characteristic | Without NR3C1 mutations | With NR3C1 mutations | p Value | |
|---|---|---|---|---|
| Case number (N = ) | 16 | 2 | ||
| Age (%) | > = 1, = <10 | 14 (87.5) | 0 (0.0) | 0.039 |
| <1, >10 | 2 (12.5) | 2 (100.0) | ||
| Gender (%) | Female | 7 (43.8) | 1 (50.0) | 1 |
| Male | 9 (56.2) | 1 (50.0) | ||
| WBC (%) | <50 × 109/L | 16 (100.0) | 2 (100.0) | NA |
| Liver (%) | <2 cm | 10 (62.5) | 1 (50.0) | 1 |
| > = 2, <5 cm | 4 (25.0) | 1 (50.0) | ||
| > = 5 cm | 2 (12.5) | 0 (0.0) | ||
| Spleen (%) | <2 cm | 10 (71.4) | 1 (100.0) | 1 |
| > = 2, <5 cm | 4 (28.6) | 0 (0.0) | ||
| > = 5 cm | 16 (100.0) | 2 (100.0) | NA | |
| Immunophenotype (%) | B-ALL | 16 (100.0) | 2 (100.0) | NA |
| Fusion genes (%) | Not identified | 10 (62.5) | 1 (50.0) | 0.641 |
| ETV6-RUNX1 | 3 (18.8) | 1 (50.0) | ||
| E2A-fusion | 1 (6.2) | 0 (0.0) | ||
| BCR-ABL | 1 (6.2) | 0 (0.0) | ||
| Others | 1 (6.2) | 0 (0.0) | ||
| BM relapse (%) | No | 4 (25.0) | 0 (0.0) | 1 |
| Yes | 12 (75.0) | 2 (100.0) | ||
| CNS relapse (%) | No | 13 (81.2) | 2 (100.0) | 1 |
| Yes | 3 (18.8) | 0 (0.0) | ||
| Testis relapse (%) | No | 11 (68.8) | 2 (100.0) | 1 |
| Yes | 5 (31.2) | 0 (0.0) | ||
| Combination relapse (%) | No | 13 (81.2) | 2 (100.0) | 1 |
| Yes | 3 (18.8) | 0 (0.0) | ||
| Risk stratification (%) | Standard risk | 4 (25.0) | 0 (0.0) | 0.255 |
| Intermediate risk | 11 (68.8) | 1 (50.0) | ||
| High risk | 1 (6.2) | 1 (50.0) |
NA, not applicable.